Glaukos - GKOS Stock Forecast, Price & News

9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Glaukos in the last twelve months. There are currently 4 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" GKOS shares.
View GKOS analyst ratings or view top-rated stocks.

9 brokerages have issued 12 month target prices for Glaukos' shares. Their GKOS share price forecasts range from $44.00 to $68.00. On average, they predict the company's share price to reach $56.67 in the next year. This suggests a possible upside of 15.2% from the stock's current price.
View analysts price targets for GKOS or view top-rated stocks among Wall Street analysts.

Glaukos' stock was trading at $43.68 on January 1st, 2023. Since then, GKOS stock has increased by 12.6% and is now trading at $49.19.
View the best growth stocks for 2023 here.

Glaukos saw a increase in short interest in February. As of February 28th, there was short interest totaling 4,720,000 shares, an increase of 5.6% from the February 13th total of 4,470,000 shares. Based on an average trading volume of 398,600 shares, the short-interest ratio is currently 11.8 days. Approximately 10.3% of the shares of the company are short sold.
View Glaukos' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 3rd 2023.
View our GKOS earnings forecast.

Glaukos Co. (NYSE:GKOS) released its quarterly earnings data on Wednesday, February, 22nd. The medical instruments supplier reported ($0.53) EPS for the quarter, beating analysts' consensus estimates of ($0.56) by $0.03. The medical instruments supplier earned $71.23 million during the quarter, compared to the consensus estimate of $67.71 million. Glaukos had a negative net margin of 35.07% and a negative trailing twelve-month return on equity of 18.51%.

ETFs with the largest weight of Glaukos (NYSE:GKOS) stock in their portfolio include Invesco S&P SmallCap Health Care ETF (PSCH), SPDR S&P Health Care Equipment ETF (XHE), ROBO Global Healthcare Technology and Innovation ETF (HTEC), Principal Healthcare Innovators ETF (BTEC), Xtrackers S&P SmallCap 600 ESG ETF (SMLE), SPDR S&P SmallCap 600 ESG ETF (ESIX), SPDR S&P 600 Small Cap Growth ETF (SLYG) and iShares S&P Small-Cap 600 Growth ETF (IJT).

Glaukos updated its FY 2023 earnings guidance on Wednesday, February, 22nd. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $290.00 million-$295.00 million, compared to the consensus revenue estimate of $304.65 million.

10 employees have rated Glaukos Chief Executive Officer Thomas W. Burns on Glassdoor.com. Thomas W. Burns has an approval rating of 100% among the company's employees. This puts Thomas W. Burns in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Glaukos investors own include NVIDIA (NVDA), Marvell Technology (MRVL), PTC Therapeutics (PTCT), PayPal (PYPL), QUALCOMM (QCOM), Alibaba Group (BABA), Teladoc Health (TDOC), Intel (INTC), Advanced Micro Devices (AMD) and Boeing (BA).

(GKOS) raised $76 million in an initial public offering on Thursday, June 25th 2015. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. J.P. Morgan, BofA Merrill Lynch and Goldman Sachs acted as the underwriters for the IPO and William Blair and Cantor Fitzgerald were co-managers.

Glaukos trades on the New York Stock Exchange (NYSE) under the ticker symbol "GKOS."

Glaukos' stock is owned by many different institutional and retail investors. Top institutional shareholders include Artisan Partners Limited Partnership (3.99%), Braidwell LP (3.48%), Fred Alger Management LLC (2.78%), Point72 Asset Management L.P. (2.42%), Geode Capital Management LLC (1.74%) and Morgan Stanley (1.70%). Insiders that own company stock include Gilbert H Kliman, Joseph E Gilliam, Thomas William Burns and William J Phd Link.
View institutional ownership trends.

Shares of GKOS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of GKOS stock can currently be purchased for approximately $49.19.

Glaukos (NYSE:GKOS) has a market capitalization of $2.36 billion and generates $282.86 million in revenue each year. The medical instruments supplier earns $-99,190,000.00 in net income (profit) each year or ($2.09) on an earnings per share basis.

The company employs 727 workers across the globe.

Glaukos' mailing address is 229 AVENIDA FABRICANTE, SAN CLEMENTE CA, 92672. The official website for the company is www.glaukos.com. The medical instruments supplier can be reached via phone at (949) 367-9600, via email at investors@glaukos.com, or via fax at 949-367-9984.